SE9704870D0 - New pharmaceutical formulation I - Google Patents

New pharmaceutical formulation I

Info

Publication number
SE9704870D0
SE9704870D0 SE9704870A SE9704870A SE9704870D0 SE 9704870 D0 SE9704870 D0 SE 9704870D0 SE 9704870 A SE9704870 A SE 9704870A SE 9704870 A SE9704870 A SE 9704870A SE 9704870 D0 SE9704870 D0 SE 9704870D0
Authority
SE
Sweden
Prior art keywords
dosage form
atpase inhibitor
pharmaceutical formulation
new pharmaceutical
released
Prior art date
Application number
SE9704870A
Other languages
English (en)
Swedish (sv)
Inventor
Per Johan Lundberg
Brita Sjoeblom
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9704870A priority Critical patent/SE9704870D0/xx
Publication of SE9704870D0 publication Critical patent/SE9704870D0/xx
Priority to ZA9811234A priority patent/ZA9811234B/xx
Priority to TW087120441A priority patent/TWI240637B/zh
Priority to ARP980106245A priority patent/AR017202A1/es
Priority to MA25384A priority patent/MA26577A1/fr
Priority to DZ980296A priority patent/DZ2686A1/xx
Priority to TNTNSN98230A priority patent/TNSN98230A1/fr
Priority to PCT/SE1998/002369 priority patent/WO1999032093A1/en
Priority to CZ20002313A priority patent/CZ299227B6/cs
Priority to YU36600A priority patent/YU36600A/sh
Priority to AT98964632T priority patent/ATE252379T1/de
Priority to ES98964632T priority patent/ES2209240T3/es
Priority to PL98341565A priority patent/PL341565A1/xx
Priority to CNB988137402A priority patent/CN1245155C/zh
Priority to TR2000/01982T priority patent/TR200001982T2/xx
Priority to DK98964632T priority patent/DK1043977T3/da
Priority to PT98964632T priority patent/PT1043977E/pt
Priority to NZ505135A priority patent/NZ505135A/en
Priority to BR9814389-1A priority patent/BR9814389A/pt
Priority to CA002315927A priority patent/CA2315927C/en
Priority to HR20000381 priority patent/HRP20000381B1/xx
Priority to EP98964632A priority patent/EP1043977B1/de
Priority to HK01105215.7A priority patent/HK1034668B/xx
Priority to SK808-2000A priority patent/SK284545B6/sk
Priority to HU0200618A priority patent/HUP0200618A3/hu
Priority to IDW20001201A priority patent/ID27040A/id
Priority to UA2000063359A priority patent/UA69396C2/uk
Priority to JP2000525085A priority patent/JP4907765B2/ja
Priority to DE69819205T priority patent/DE69819205T2/de
Priority to IL13682398A priority patent/IL136823A/xx
Priority to EEP200000395A priority patent/EE04417B1/xx
Priority to KR1020007006907A priority patent/KR100616027B1/ko
Priority to US09/555,720 priority patent/US6610323B1/en
Priority to RU2000116012/14A priority patent/RU2205028C2/ru
Priority to AU19913/99A priority patent/AU759311B2/en
Priority to SI9830589T priority patent/SI1043977T1/xx
Priority to MYPI98005795A priority patent/MY130765A/en
Priority to EG158698A priority patent/EG23875A/xx
Priority to IS5541A priority patent/IS2184B/is
Priority to NO20003219A priority patent/NO20003219L/no
Priority to BG104619A priority patent/BG65008B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9704870A 1997-12-22 1997-12-22 New pharmaceutical formulation I SE9704870D0 (sv)

Priority Applications (41)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I
ZA9811234A ZA9811234B (en) 1997-12-22 1998-12-08 Oral pharmaceutical pulsed release dosage form
TW087120441A TWI240637B (en) 1997-12-22 1998-12-09 Oral pharmaceutical pulsed release dosage form
ARP980106245A AR017202A1 (es) 1997-12-22 1998-12-09 Forma de dosificacion farmaceutica oral de liberacion pulsada y procedimiento para la preparacion de la misma y su uso para la manufactura de unmedicamento
MA25384A MA26577A1 (fr) 1997-12-22 1998-12-11 Formulation pharmaceutique orale a liberation pulsee
DZ980296A DZ2686A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale à libération pulsée.
TNTNSN98230A TNSN98230A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale a liberation pulsee
SI9830589T SI1043977T1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
BR9814389-1A BR9814389A (pt) 1997-12-22 1998-12-17 Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
HU0200618A HUP0200618A3 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form and process for its preparation
YU36600A YU36600A (sh) 1997-12-22 1998-12-17 Oralni farmaceutski oblik za doziranje sa pulsnim oslobađanjem
AT98964632T ATE252379T1 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
ES98964632T ES2209240T3 (es) 1997-12-22 1998-12-17 Formas de dosificacion farmaceutica oral de liberacion por pulsos.
PL98341565A PL341565A1 (en) 1997-12-22 1998-12-17 Oral dosage form featured by pulse-type release of active substance
CNB988137402A CN1245155C (zh) 1997-12-22 1998-12-17 口服药用脉冲释放剂型
TR2000/01982T TR200001982T2 (tr) 1997-12-22 1998-12-17 Farmasötik vurulu salınımlı oral dozaj şekli.
DK98964632T DK1043977T3 (da) 1997-12-22 1998-12-17 Oral farmaceutisk doseringsform baseret på pulserende frigørelse
PT98964632T PT1043977E (pt) 1997-12-22 1998-12-17 Forma de dosagem farmaceutica oral de libertacao por impulsos
NZ505135A NZ505135A (en) 1997-12-22 1998-12-17 Composition comprising a proton pump inhibitor (H+,K+-ATPase inhibitor) which provides two or more discrete release pulses in the small and/or large intestines
PCT/SE1998/002369 WO1999032093A1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
CA002315927A CA2315927C (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
HR20000381 HRP20000381B1 (en) 1997-12-22 1998-12-17 Stable complexes of poorly soluble compounds
EP98964632A EP1043977B1 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
HK01105215.7A HK1034668B (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
SK808-2000A SK284545B6 (sk) 1997-12-22 1998-12-17 Orálna farmaceutická dávková forma s pulzačným uvoľňovaním
CZ20002313A CZ299227B6 (cs) 1997-12-22 1998-12-17 Enterálne potažená farmaceutická dávková forma, zpusob prípravy a použití této dávkové formy, jakoži vrstvená tableta nebo peleta pro dávkovou formu
IDW20001201A ID27040A (id) 1997-12-22 1998-12-17 Bentuk sediaan dengan pelepasan berpulsa dari bahan farmasi oral
UA2000063359A UA69396C2 (uk) 1997-12-22 1998-12-17 ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА З ДИСКРЕТНИМ ВИВІЛЬНЕННЯМ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ (ВАРІАНТИ) ТА СПОСІБ ЇЇ ОДЕРЖАННЯ (ВАРІАНТИ) І СПОСІБ ЛІКУВАННЯ (ВАРІАНТИ)
JP2000525085A JP4907765B2 (ja) 1997-12-22 1998-12-17 経口医薬パルス放出剤形
DE69819205T DE69819205T2 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform beruhend auf stossweiser freisetzung
IL13682398A IL136823A (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
EEP200000395A EE04417B1 (et) 1997-12-22 1998-12-17 Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm, selle valmistamise meetod ja kasutamine
KR1020007006907A KR100616027B1 (ko) 1997-12-22 1998-12-17 경구용 제약학적 펄스 방출형 투여 제형
US09/555,720 US6610323B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
RU2000116012/14A RU2205028C2 (ru) 1997-12-22 1998-12-17 Пероральная фармацевтическая лекарственная форма с дискретным высвобождением
AU19913/99A AU759311B2 (en) 1997-12-22 1998-12-17 Oral pharmaceutical pulsed release dosage form
EG158698A EG23875A (en) 1997-12-22 1998-12-21 Oral pharmaceutical pulsed release dosage form
MYPI98005795A MY130765A (en) 1997-12-22 1998-12-21 Oral pharmaceutical pulsed release dosage form
IS5541A IS2184B (is) 1997-12-22 2000-06-19 Lyfjaform með áfangalosun til inntöku um munn
NO20003219A NO20003219L (no) 1997-12-22 2000-06-21 Oral farmasøytisk doseringsform med pulsert frigivningsvirkning
BG104619A BG65008B1 (bg) 1997-12-22 2000-07-17 Орална лекарствена дозирана форма с импулсно освобождаване

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Publications (1)

Publication Number Publication Date
SE9704870D0 true SE9704870D0 (sv) 1997-12-22

Family

ID=20409572

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704870A SE9704870D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulation I

Country Status (39)

Country Link
US (1) US6610323B1 (de)
EP (1) EP1043977B1 (de)
JP (1) JP4907765B2 (de)
KR (1) KR100616027B1 (de)
CN (1) CN1245155C (de)
AR (1) AR017202A1 (de)
AT (1) ATE252379T1 (de)
AU (1) AU759311B2 (de)
BG (1) BG65008B1 (de)
BR (1) BR9814389A (de)
CA (1) CA2315927C (de)
CZ (1) CZ299227B6 (de)
DE (1) DE69819205T2 (de)
DK (1) DK1043977T3 (de)
DZ (1) DZ2686A1 (de)
EE (1) EE04417B1 (de)
EG (1) EG23875A (de)
ES (1) ES2209240T3 (de)
HR (1) HRP20000381B1 (de)
HU (1) HUP0200618A3 (de)
ID (1) ID27040A (de)
IL (1) IL136823A (de)
IS (1) IS2184B (de)
MA (1) MA26577A1 (de)
MY (1) MY130765A (de)
NO (1) NO20003219L (de)
NZ (1) NZ505135A (de)
PL (1) PL341565A1 (de)
PT (1) PT1043977E (de)
RU (1) RU2205028C2 (de)
SE (1) SE9704870D0 (de)
SK (1) SK284545B6 (de)
TN (1) TNSN98230A1 (de)
TR (1) TR200001982T2 (de)
TW (1) TWI240637B (de)
UA (1) UA69396C2 (de)
WO (1) WO1999032093A1 (de)
YU (1) YU36600A (de)
ZA (1) ZA9811234B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
US7041313B1 (en) 1998-08-12 2006-05-09 Altana Pharma Ag Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
JP2000128779A (ja) * 1998-10-20 2000-05-09 Mitsui Chemicals Inc 薬物放出制御型製剤
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2295043A1 (de) 1999-10-29 2011-03-16 Euro-Celtique S.A. Hydrocodon-Formulierungen mit gesteuerter Freisetzung
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
EP1556024A4 (de) * 2002-10-25 2007-01-17 Collegium Pharmaceutical Inc Zusammensetzungen von milnacipran mitpulsativer freisetzung
EP1581196A4 (de) * 2002-12-23 2007-08-22 Celltech Americas Inc Säurelabile arzneimittelzusammensetzungen
JP2004231520A (ja) * 2003-01-28 2004-08-19 Nichiko Pharmaceutical Co Ltd 保存安定性及び溶出速度に優れた医薬組成物
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
ATE419841T1 (de) * 2003-09-03 2009-01-15 Pharmaton Sa Kapseln enthaltend wirkstoffpellets mit unterschiedlichen freisetzungsprofilen
EP1663169A4 (de) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotisches produkt, seine verwendung und formulierung
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
NZ546183A (en) * 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
DE602004032149D1 (de) * 2003-09-26 2011-05-19 Alza Corp Oros-push-stick für die kontrollierte abgabe von wirkstoffen
NZ546182A (en) * 2003-09-26 2009-08-28 Alza Corp Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP2005272347A (ja) * 2004-03-24 2005-10-06 Ohara Yakuhin Kogyo Kk 固形製剤の製造方法
BRPI0509135A (pt) * 2004-03-26 2007-08-28 Eisai R&D Man Co Ltd composição farmacêutica de liberação controlada e método para produzir a mesma
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8461187B2 (en) * 2004-06-16 2013-06-11 Takeda Pharmaceuticals U.S.A., Inc. Multiple PPI dosage form
AU2011205024B2 (en) * 2004-06-16 2012-09-06 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
AR052225A1 (es) * 2004-11-04 2007-03-07 Astrazeneca Ab Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
US7226454B2 (en) * 2004-12-07 2007-06-05 Arizant Healthcare Inc. Warming device with varied permeability
WO2006111853A2 (en) * 2005-04-18 2006-10-26 Aurobindo Pharma Limited Stable solid dosage forms of acid labile drug
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
CN101389316A (zh) 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
EP1967184A4 (de) * 2005-12-28 2011-02-16 Takeda Pharmaceutical Feste zubereitung mit kontrollierter freisetzung
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
US9504678B2 (en) 2006-04-04 2016-11-29 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an acid inhibitor
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US20100297226A1 (en) * 2006-06-01 2010-11-25 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
EP2046334B1 (de) 2006-07-25 2014-05-21 Vecta Ltd. Zusammensetzungen und verfahren zur hemmung von magensäuresekretion anhand von derivaten kleiner dicarbonsäuren in kombination mit ppi
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
EP1970056A1 (de) * 2007-03-15 2008-09-17 Polichem S.A. Zeitspezifische Dosierformen mit verzögerter/pulsatiler Freisetzung
US20100104656A1 (en) * 2007-03-20 2010-04-29 Paul Wan Sia Heng Meltable Binder for Melt Granulation and/or Pelletization
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
AU2009230676A1 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
KR20110079641A (ko) 2008-09-09 2011-07-07 아스트라제네카 아베 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법
NZ597534A (en) * 2009-06-25 2013-09-27 Pozen Inc Method for treating a patient in need of aspirin therapy
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
WO2012051495A2 (en) * 2010-10-15 2012-04-19 The Research Foundation Of State University Of New York Compositions and methods for enhancing the biological response to chemical agents and physical stimuli
US9539214B2 (en) 2011-12-28 2017-01-10 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JP6905972B2 (ja) * 2016-02-23 2021-07-21 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
KR101884230B1 (ko) * 2016-02-29 2018-08-01 주식회사 유영제약 에소메프라졸을 포함하는 제제
CN105796531A (zh) * 2016-04-13 2016-07-27 中国药科大学 一种右旋兰索拉唑择时脉冲控释微丸制剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JP6915258B2 (ja) * 2016-10-21 2021-08-04 ニプロ株式会社 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
CN109125282B (zh) * 2018-09-05 2020-07-14 珠海润都制药股份有限公司 一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5330982A (en) 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
GB8903564D0 (en) 1989-02-16 1989-04-05 Rashid Abdul Drug dispensing device
HU207940B (en) 1989-02-16 1993-07-28 British Tech Group Feeder apparatus for controlled dissolution of the active components
US5229131A (en) * 1990-02-05 1993-07-20 University Of Michigan Pulsatile drug delivery system
JPH04273816A (ja) * 1991-02-26 1992-09-30 Tanabe Seiyaku Co Ltd パルス放出型有核錠
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
JPH072650A (ja) 1993-06-18 1995-01-06 Tanabe Seiyaku Co Ltd 放出部位制御型製剤
SE9302395D0 (sv) 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
DK1078628T3 (da) * 1994-07-08 2009-02-23 Astrazeneca Ab Tabletteret flerenhedsdoseringsform
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH08157392A (ja) * 1994-12-01 1996-06-18 Kanegafuchi Chem Ind Co Ltd 放出制御型製剤
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5567441A (en) 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) * 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals

Also Published As

Publication number Publication date
DK1043977T3 (da) 2004-02-09
JP4907765B2 (ja) 2012-04-04
ATE252379T1 (de) 2003-11-15
JP2001526213A (ja) 2001-12-18
HUP0200618A2 (hu) 2002-07-29
EE200000395A (et) 2002-02-15
CA2315927A1 (en) 1999-07-01
AU1991399A (en) 1999-07-12
NO20003219L (no) 2000-08-22
EE04417B1 (et) 2005-02-15
BG104619A (en) 2001-04-30
HK1034668A1 (en) 2001-11-02
IL136823A (en) 2005-08-31
HUP0200618A3 (en) 2003-04-28
EP1043977A1 (de) 2000-10-18
IL136823A0 (en) 2001-06-14
NZ505135A (en) 2002-06-28
CZ299227B6 (cs) 2008-05-21
ES2209240T3 (es) 2004-06-16
CA2315927C (en) 2008-03-18
US6610323B1 (en) 2003-08-26
CZ20002313A3 (cs) 2000-11-15
DE69819205T2 (de) 2004-08-26
PT1043977E (pt) 2004-03-31
DZ2686A1 (fr) 2003-03-29
HRP20000381B1 (en) 2004-12-31
CN1284868A (zh) 2001-02-21
BG65008B1 (bg) 2006-12-29
DE69819205D1 (de) 2003-11-27
UA69396C2 (uk) 2004-09-15
TWI240637B (en) 2005-10-01
ID27040A (id) 2001-02-22
HRP20000381A2 (en) 2000-12-31
TNSN98230A1 (fr) 2005-03-15
WO1999032093A1 (en) 1999-07-01
PL341565A1 (en) 2001-04-23
MA26577A1 (fr) 2004-12-20
SK8082000A3 (en) 2001-02-12
CN1245155C (zh) 2006-03-15
TR200001982T2 (tr) 2001-02-21
KR100616027B1 (ko) 2006-08-28
MY130765A (en) 2007-07-31
NO20003219D0 (no) 2000-06-21
YU36600A (sh) 2003-01-31
RU2205028C2 (ru) 2003-05-27
AR017202A1 (es) 2001-08-22
EP1043977B1 (de) 2003-10-22
ZA9811234B (en) 1999-06-22
IS2184B (is) 2006-12-15
EG23875A (en) 2007-11-27
IS5541A (is) 2000-06-19
AU759311B2 (en) 2003-04-10
BR9814389A (pt) 2000-10-10
SK284545B6 (sk) 2005-06-02
KR20010033427A (ko) 2001-04-25

Similar Documents

Publication Publication Date Title
YU36600A (sh) Oralni farmaceutski oblik za doziranje sa pulsnim oslobađanjem
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
NO934284D0 (no) Farmas!ytisk preparat inneholdende et definert lipidsystem
ATE252885T1 (de) Plan zur verabreichung von h+, k+-atpase inhibitoren
HRP20020158B1 (en) Action of synergistic combination
ATE324872T1 (de) Orale pharmazeutische zusammensetzung mit verzögerter wirkstofffreigabe von protonenpumpen- hemmern
MXPA02007931A (es) Analogos de nucleosido con base monociclica modificada con carboxamidina.
AU7239996A (en) Inhibition of tumor necrosis factor alpha
DE69516540D1 (de) AMINO-IMIDAZO [4,5-c] CHINOLINE
DE69827777D1 (de) Zusammensetzungen mit verzögerter Wirkstoffabgabe zur Behandlung der Hyperlipidämie
DE69033970D1 (de) Huperzin a analoge verbindungen
DE60019334D1 (de) Antivirale arznei
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
PT880520E (pt) Derivados da benzo¬c|quinolizina sua preparacao e uso como inibidores da 5-alfa-reductase
HRP20000704B1 (hr) Peroralni pripravci koji kontrolirano oslobađaju levosimendan
DE60126591D1 (de) In-vitro-Verwendung von Astaxanthin zur Vorbehandlung von Zellen vor UV-Bestrahlung zwecks Hemmung der Aktivierung von NF-KB
CA2225628A1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
SI0841904T1 (en) Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors
IT1270958B (it) Composizioni farmaceutiche a base di nimesulide, somministrabili per via orale, non gastrolesive e/o a rilascio controllato
NO920719L (no) Injiserbare s-adenosyl-l-metionin-holdige preparater